FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
FDA General

Turmoil, Turnover and Industry Backlash Mark Makarys Tenure

New Bloomberg reporting that FDA is facing mounting internal strain and external criticism just over a year into commissioner Marty Makarys tenure.

latest-news-card-1
Human Drugs

Clene Plans ALS Drug Filing After Input on Accelerated Path

Clene says it plans to submit an NDA in the third quarter for its experimental amyotrophic lateral sclerosis therapy.

latest-news-card-1
Human Drugs

Allergans Ireland Plant Hit With 483 After Inspection

FDA cites multiple manufacturing and quality control deficiencies at a facility operated by Allergan Pharmaceuticals in Ireland following an inspectio...

Biologics

Town Hall on BLA Submissions for Cell and Gene Therapies

FDA plans a 6/4 town hall meeting aimed at guiding drug developers through the process of preparing BLAs for cell and gene therapy products. The CBER ...

latest-news-card-1
Federal Register

PhRMA Urges Changes to FDAs Plausible Mechanism Guidance

PhRMA urges FDA to broaden and clarify its draft guidance on individualized therapies, warning that overly narrow definitions and unclear expectations...

latest-news-card-1
Human Drugs

Expanded Access Program for Promising Pancreatic Cancer Drug

FDA authorizes an expanded access program for an experimental pancreatic cancer therapy from Revolution Medicines, allowing certain patients to receiv...

latest-news-card-1
Human Drugs

Veppanu Approved for Advanced Breast Cancer

FDA has approved Arvinas Operations Veppanu (vepdegestrant) for treating certain patients with advanced breast cancer, marking the first authorization...

latest-news-card-1
Human Drugs

Eugia Pharma Specialties FDA-483 Out

FDA releases the form FDA-483 with three observations from an inspection at Indias Eugia Pharma Specialties Limited.

latest-news-card-1
Human Drugs

Keep GLP-1s Off Bulks List: FDA

FDA proposes not to include semaglutide, tirzepatide, and liraglutide on the 503 Bulks List of drugs that can be legally compounded from bulk substanc...

Marketing

Nubeqa TV Ad, Video Misleading: FDA

The CDER Office of Prescription Drug Promotion cautions Bayer that a video and TV ad for its Nubeqa omit important risk information and contain elemen...